ramon-cacabelos
Ramon Cacabelos, MD, PhD, DMSc
Professor & Chairman of Genomic Medicine

Continental University Medical School
Huancayo, Peru
Phone: +34-981-780505
E-mail: rcacabelos@euroespes.com

Education

1996 International Master of Higher Hospital Management- International School of Higher Hospital Management, Madrid, Spain
  1987 PhD, DMSci. (Doctor in Medical Science/Internal Medicine/Psychiatry)Osaka- University Medical School, Osaka, Japan
Specialist in Psychiatry- Department of Psychiatry, Osaka University Medical School, Osaka, Japan
1985 PhD (Medicine & Surgery)- Santiago University Medical School, Santiago de Compostela, Spain
1980 MD Graduate in Medicine and Surgery- Oviedo University Medical School, Oviedo, Spain

Biography

Dr. Ramón Cacabelos is Professor of Genomic Medicine at Continental University Medical School, Huancayo, Peru; and President of the EuroEspes Biomedical Research Center, Institute of Medical Science and Genomic Medicine, Corunna, Spain. He received his MD from Oviedo University, PhD from Santiago University, and DMSci. (Psychiatry) from Osaka University Medical School, Japan. After a decade at the Department of Psychiatry in Osaka, he returned to Spain and focused his research activity on the genomics and pharmacogenomics of neurodegenerative disorders. He was the founder of the first Chair of Genomic Medicine in Spain at Camilo Jose Cela University, Madrid, where he served as Vice-Rector of Research and Science. He has published over 600 papers and 24 books, and is Editor-in-Chief of the first World Guide for Drug Use and Pharmacogenomics and President of the World Association of Genomic Medicine.


Research Interest

  • Neurodegenerative disorders
  • Genomics of Brain Disorders
  • Neurogenetics
  • Drug development for CNS disorders and Dementia
  • Epigenomics
  • Pharmacogenomics of CNS disorders and Dementia

Scientific Activities

Professional Experience
2017 Professor & Chairman, Chair of Genomic Medicine, Continental University Medical School, Huancayo, Peru
2013-2016 Professor & Chairman, Chair of Genomic Medicine, Camilo José Cela University, Madrid, Spain
2013-2015 Vice-Rector of Research and Science, Camilo José Cela University, Madrid, Spain
2003-2013 Professor & Chairman, EuroEspes Chair of Biotechnology and Genomics, Camilo Jose Cela University, Madrid, Spain
2008 President, World Association of Genomic Medicine
2005 President, Spanish Society of Genomic Medicine
2003-2008 President, Ebiotec Foundation, La Coruña, Spain
2001 President, EuroEspes Biotechnology (EBIOTEC), La Coruña, Spain
1995 Director, Department of Clinical Neurosciences, CIBE, La Coruña, Spain
Director General, EuroEspes Biomedical Research Center, La Coruña, Spain
1994-2005 President, Spanish Association of Neurogerontology and Neurogeriatrics
1992-2013 President, EuroEspes Foundation
1991 Director, Institute for Central Nervous System Disorders and Genomic Medicine, La Coruña, Spain
President of EuroEspes Corp
Visiting Professor, Department of Pathology, New York University Medical Center, New York, USA
1990 Visiting Professor, Department of Psychiatry, Navarra University
1989-1995 Associate Professor, Department of Human Physiology, Complutense University Medical School, Madrid, Spain
1989-1995 Associate Professor, Department of Human Physiology, Complutense University Medical School, Madrid, Spain
1987-1989 Associate Professor of Psychiatry, Department of Psychiatry, Santiago University Medical School, Santiago de Compostela, Spain
Other Activities
  • Member of 31 Scientific Societies (National and International)
  • Referee of 70 Scientific Journals (National and International)
  • Member of 64 International Professional Committees
  • 168 Headed Research Projects (National and International) and 7 Patents

Publications

  1. Cacabelos R. Proteomic biomarkers in Alzheimer’s disease. Diagn Pathol Open 2016; 1:1. http://dx.doi.org/10.4172/DPO.1000103.
  2. Cacabelos R. Nutriepigenomics: Mending ideas in nutrition, health and disease. J Nutr Sci 2016; 6:1. http://doi.org/10.4172/2155-9600.100e124.
  3. Aliev G, Cacabelos R, Prakash Reddy V. Neurodegeneration, oxidative stress, metabolic syndrome, drug design and development: Clinical implications. CNS & Neurological Disroders-Drug Targets 2016; 15(2): 126.
  4. Cacabelos R, Torrellas C, Carrera I, Cacabelos P, Corzo L, Fernández-Novoa L, Tellado I, Carril JC, Aliev G. Novel therapeutic strategies for Dementia. CNS & Neurological Disroders-Drug Targets 2016; 15(2): 141-241.
  5. Cacabelos R1,2, Teijido O1,3, Carril JC1,4. Can cloud-based tools accelerate Alzheimer's disease drug discovery? Expert Opin Drug Discov. 2016 Jan 14. [Epub ahead of print]
  6. Cacabelos R. ADHD: Challenges for a better future. Gen-T International 2016; 4: 3-5.
  7. Cacabelos R, Torrellas C, Tellado I, Cacabelos P. Genomics, pathogenesis, treatment and Pharmacogenomics of attention-deficit/hyperactivity disorder. Gen-T International 2016; 4:8-134.
  8. Cacabelos R, Torrellas C, Fernández-Novoa L, Aliev G. Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection. Curr Pharm Des. 2016; 22 (7): 819-48.
  9. Carrera I, Fernandez-Novoa L, Aliev G, Vigo C, Cacabelos R. Validating Immunotherapy in Alzheimer's Disease: The EB101 Vaccine. Curr Pharm Des. 2016; 22 (7): 849-58.
  10. Cacabelos R. Trial-and-Error versus Personalized Treatment in Depression: The Power of Pharmacogenomics. J Psychiatry Depress Anxiety 2016; 2: 004.
  11. Cacabelos R. Histamine: The Missing Link in the Pathogenesis of Some Brain Disorders. Journal of Clinical and Experimental Neuroimmunology 2016; 1:1. doi:10.4172/jceni.1000103.
  12. Cacabelos R. Epigenetics of Brain Disorders: The Paradigm of Alzheimer’s disease. J Alzheimers Dis Parkinsonism 2016; 6:229. doi: 10.4172/2161-0460.1000220.
  13. Cacabelos R. The complexity of Alzheimer’s disease pharmacogenomics and metabolomics in drug development. Metabolomics 2016; 2:6. doi: 10.4172/2153-0769.1000e145.
  14. Cacabelos R, Torrellas C, Teijido O, Carril JC. Pharmacogenetic considerations in the treatment of Alzheimer's disease. Pharmacogenomics. 2016 Jun; 17(9):1041-74. doi: 10.2217/pgs-2016-0031. Epub 2016 Jun 13.
  15. Cacabelos R, Torrellas C, Fernández-Novoa L, López-Muñoz F. Histamine and Immune Biomarkers in CNS Disorders. Mediators Inflamm. 2016; 2016:1924603. doi: 10.1155/2016/1924603. Epub 2016 Apr 13.
  16. Cacabelos R. Biochemical changes and cardiovascular function in Parkinson’s disease: Precautionary notes. Clin Med Biochemistry Open Access 2016; 2:2. doi:10.4172/2471-2663.1000e102.
  17. Cacabelos R. Genomic Medicine: A conceptual revolution in medical practice. J Genomic Med Pharmacogenomics 2016; 1:1-2.
  18. Cacabelos R, Fernández-Novoa L, Alejo R, Corzo L, Alcaraz M, Nebril L, Cacabelos P, Fraile C, Carrera I, Carril JC. E-PodoFavalin-15999 (Atremorine®)-induced dopamine response in Parkinson’s Disease: Pharmacogenetics-related effects. J Genomic Med Pharmacogenomics 2016; 1:1-26.
  19. Carril JC, Cacabelos R. Genomics and Pharmacogenomics of cerebrovascular disorders. J Genomic Med Pharmacogenomics 2016; 1:27-75.
  20. Arun M, Gomathi M,Mahalaxmi I, Kumat AK, Balamuralikrishnan B, Kumar R, Kumar M, Easwaran M, Raman N, Gowtham M, Sureshkumar S, Haripriya KB, Elipilla P, Balchandar V, Sasikala K, Cacabelos R. Cytogenetics and selected biochemical phenotypes in Indian schizophrenic patients. J Genomic Med Pharmacogenomics 2016; 1: 81-94.
  21. Teijido O, Cacabelos R. Interrogating the epigenome to unveil the secrets of neurodegeneration: Promising epigenetic therapies. J Genomic Med Pharmacogenomics 2016; 1: 95-150.
  22. Cacabelos R. Parkinson’s disease: Old concepts and new challenges. Scientific Pages Alzheimers Dis Dement 2016; 1: 001.

Aging Studies and Therapies Flyer